Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARU 1801

Next Previous
Drug Profile

ARU 1801

Alternative Names: ARU-1801; RVT-1801

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cincinnati Childrens Hospital Medical Center
  • Developer Aruvant Sciences; Cincinnati Childrens Hospital Medical Center
  • Class Antianaemics; Gene therapies; Haematopoietic stem cells therapies; Stem cell therapies
  • Mechanism of Action Fetal haemoglobin replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 31 Oct 2022 Children's Hospital Medical Center terminates a phase-I/II clinical trials in Sickle cell anaemia in USA (Parenteral), Jamaica (Parenteral) due to funding issues (NCT02186418)
  • 28 Jun 2022 Discontinued (due to company-wide cost optimization and pipeline reprioritization)- Phase-II for Sickle cell anaemia in Jamaica (IV), USA (IV)
  • 28 Jun 2022 Discontinued (due to company-wide cost optimization and pipeline reprioritization)- Preclinical for Beta-thalassaemia in Switzerland (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top